

Curriculum Vitae : Jean-Marc EGLY.

Education

PhDs in Chemistry (1970), in Biochemistry (1976), Strasbourg.

Graduated in Environmental Sciences (DES), (1972) Strasbourg.

Post.Doc (1977) Department of Biochemistry (Pr. J. Porath Uppsala, Sweden).

Professional experience:

Research Director, INSERM (U1258; Strasbourg)

Member of the Science Academy (2005)

Distinguished Prof. at the National Taiwan University (2016 - 2021)

EMBO Member (2002)

Prof. at the Ecole Supérieure de Biotechnologie de Strasbourg (1982-1993)

Expert in Molecular Biology, Protein Chemistry, Biotechnology; Design of 15 products for chromatography.

Author of 285 publications: Cell, Mol. Cell., Nature, Nat. Gen., Nat. Neuro., Nat. SMB., Science, EMBO, JBC.

Invited speaker, Keynotes at J. Monod, UCLA, Gordon, FEBS, IUB, Cold Spring Harbor and EMBO Meetings.

Scientific Boards:

- Oklahoma Medical Research Foundation (USA; 1996-00); Nation Research Agency against Aids (Paris, 1997-02); French Delegate Biology, Medicine and Health Program (E.E.C., Brussels 1997-01); National Sequencing Center GENOSCOPE (Evry, Fr.; President; 1997-01); NATO, Cooperative Life Science and Technology (Brussels, 1999-02); Fondation pour la Recherche Medicale (2000-03); Institut Curie (Paris, 1998-03); EUROGENTEC (Be., 2000-2010) ; Pharma-Mar (2007-), Inst. de Biol. Mole e Celular – IBMC (Porto, Portugal) .
 - Scientific Advisor near the Life Science Dept. CEO of Commissariat at the Atomic Energy (2003-07).
 - Editorial Board of EMBO, Protein Purification, Molecular Endocrinology, DNA repair, Transcription
 - Member of EMBO (1997) and of the American Society for Biochemistry and Molecular Biology (ASBMB).
 - Member of the Swiss National Foundation: Evaluation of all the 12 years grants since 2003 (Feb-Mai 2014)
 - . Chairman of the Scientific Council of the Association de la Recherche contre le Cancer (2006-2012)
 - . President of «Comité Avenir INSERM/CNRS» for recruiting high-level young investigators (2004-14)
 - . Chairman of Scientific Council of the Inst.de Rech. Cancer de l'Appareil Dig.(2004-14)
 - . Scientific Advisor near the Chairman of Inserm (2007-14)
 - . Chairman of Scientific Council of Albert-Bonniot (Grenoble); Université de Toulouse
 - . Member of the Parliamentary Office for Strategic & Technologic Projects Evaluation (Paris, 1998- 2016)
 - . Member (9 members) of the Conseil de Prospective of the de French National Research Agency (2008-2016)
-

At the present

- . Scientific Advisory Boards at: Centre de Recherche sur le Cancer de Toulouse (CRCT) (2014-...); I; Institut Gustave Roussy (IGR), Villejuif,Fr (2016-...).
- . Chairman of SAB Institute for Research on Cancer and Ageing of Nice (IRCAN) (2010- ...)

- Member of the Scientific Council of Institut de Recherche sur le Developpement (IRD) (2017-2021)
- Scientific Adviser of Ksilink, a company with expertise in personalized medicine and drugs evaluation
- Grants with Korea NSF (2014-2021), Spain (Pharma-Mar 2020) and ARC (2016-2019).
- **Mount Jade Scholar grant** from the MOST Taiwan (Oct 2018-Sept 2021)

Awards

- Chevalier de l'Ordre National du Mérite (1996); Officier de la Légion d'Honneur (2014).
- Tartois Award, Fondation pour la Recherche Médicale (1996).
- European Award Jeanne Loubresse-Institut Curie for Advances in Cancer Research (1997).
- **Descartes Research Award from the European Union (2000).**
- AGF/Athena Award from the French Science Academy (2002).
- **Grand Prix Institut National de la Santé et de la Recherche Medicale (INSERM) (2004).**
- **Member of the French Science Academy (2006).**
- Duquesne Award from the Ligue nationale contre le Cancer de la ville de Paris (2009)
- Mitjaville Award from the French Académie Nationale de Médecine (2009)
- **Grand Prix de la Fondation pour la Recherche Medicale (2012).**
- **European Research Council Advanced Grant Award: Top 5% (2009-2013).**
- **Chercheur Top 1% according to the web of knowledge (H index 77), 17,000 citations.**

Selected publications between 1990 and 2016 (among 270)

1. **TBP** : Cavallini et al. , A yeast activity can substitute for the HeLa cell TATA box factor., **Nature** (1988) 334, 77-80.
Cavalini et al., Cloning of the gene encoding the yeast protein BTF1Y, which can substitute for the human TATA box-binding factor **PNAS** (1989) 86, 9803-7.; Davison BL, Formation of stable preinitiation complexes between eukaryotic class B transcription factors and promoter sequences **Nature** (1983) 301, 680-6.

TFIIH :

2. Gerard, M., Fischer, L., Moncollin, V., Chipoulet and **Egly, J.M.** Purification and interaction properties of the human RNA polymerase B general transcription factor BTF2 (TFIIH). **J. Biol. Chem.** (1991) 266, 20940-20945.

3. Fisher, L., Gerard, M., Chalut, C., Lutz, Y., Humbert, S., Kanno, M., Chambon, P., and **Egly, J.M.** Cloning of the 62kD component of the basic transcription factor BTF2. **Science** (1992), 257, 1392-1395.

4. Lu,H., Zawel,L., Fisher,L., **Egly,J.M.** and Reinberg D. Human general transcription factor TFIIH phosphorylates the CTD-tail of RNA Polymerase II. **Nature** (1992), 358,641-645.

5. Schaeffer L., Roy R., Humbert S., Moncollin V., Vermeulen W., Hoeijmakers J.H.J., Chambon P. and **Egly J.M.** The basic transcription factor BTF2/TFIIH contains a helicase involved in both transcription and DNA repair. **Science** (1993), 260, 58-63. (**Science N&V : DNA repair : molecule of the year**).

6. Humbert S., van Vuuren H., Lutz Y., Hoeijmakers J.H.J., **Egly J.M.**, Moncollin V. Characterization of p44 and p34 subunits of the BTF2/TFIIH transcription repair factor. **EMBO** (1994), 13, 2393-2398.


7. Van Vuuren A.J., Vermeulen W., Ma L., Weeda G., Appeldorn E. Jaspers N.G.J. van der Eb A.J., Hoeijmakers J.H.J and Humbert S., Shaeffer L., **Egly J.M.** Correction of Xeroderma repair defect by basal transcription factor BTF2/TFIIH. **EMBO** (1994), 13, 1645-1653.

8. Schaeffer L., Moncollin V., Roy R., Staub A., Mezzina V., Sarazin A., Weeda G., Hoeijmakers J.H.J. and **Egly J.M.** The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. **EMBO** (1994), 13, 2388-2392.



9. Roy R., Adamczewski J.P., Seroz T., Vermeulen W., Tassan J.P. Schaeffer L., Nigg E.A., Hoeijmakers J.H.J. and **Egly J.M.** MO15 kinase involved in cell cycle regulation is part of TFIIH the transcription/DNA repair factor. *Cell* (1994), 79, 1-9.
10. Aboussekra A., Biggerstaff M., Shivji M., Vilpo J., Moncollin V., Podust V., Protic M., Hubsher U., **Egly J.M** and Wood R.D. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. *Cell* (1995), 80, 859-868.
11. Adamczewski J.P., Rossignol M., Tassan J.P., Nigg E.A., Moncollin V. and **Egly J.M.** MAT1, cdk7 and cyclin H form a kinase complex which is UV light sensitive upon association with TFIIH. *EMBO* (1996), 15, 1877-1884.
12. Marinoni J.C., R. Roy , W. Vermeulen , P. Miniou , Y. Lutz, G. Weeda, T. Seroz, E. Viegas-Péquignot, J.H.J. Hoeijmakers and **J.M. Egly** Cloning and characterization of p52, the fifth subunit of the core of the transcription/DNA repair factor TFIIH. *EMBO* (1997), 16, 1093-1102.
13. Rossignol M., Kolb-Cheynel I. and **Egly J.M.** Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH. *EMBO* (1997), 16, 1628-1637.
- 14 Rochette-Egly C., Adam S., Rossignol M., **Egly J.M.** and Chambon P. Stimulation of the activation function of RAR a through binding to the general transcription factor TFIIH and phosphorylation of cdk7. *Cell* (1997), 90, 97-107.
15. Vichi P., Coin F., Vermeulen W., Renaud J-P., J.H.J. Hoeijmakers, Moras D., and **Egly J.M.** Cisplatin- and UV-damaged DNA lure the basal transcription factor TBP/TFIID. *EMBO* (1997) 16, 7444-7456.
16. Coin F., Marinoni J.C., Rodolfo C., Fribourg S., Pedrini M.A. and **Egly J.M.** Mutations in XPD helicase prevent its interaction and regulation by p44 another subunit of TFIIH, resulting in XP and TTD phenotypes. *Nature gen.* (1998) 20, 184-189. (N&V)
17. Tirode F., Busso F., Coin F. and **Egly J.M.** Reconstitution of the transcription factor TFIIH: Assignment of functions for the three enzymatic subunits XPB, XPD and cdk7. *Molecular Cell* (1999), 3, 1-9.
18. Coin F., Bergmann E., Tremaud-Bravard A. and **Egly J.M.** Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH in transcription. *EMBO* (1999), 18, 1357-1366.
19. Araujo S. J., Tirode F., Coin F., Syvaaja J., Pospeich H., Syvaaja J. E., Stucki M., Hubscher U., **Egly J.M.** Wood R.D. Nucleotide excision repair of DNA lesion with recombinant human protein. Definition of the minimal set of factors, active forms of TFIIH and modulation by CAK. *Gen. and Dev.* (2000), 14, 349-359.
20. Chen D., Riedl Th., Washbrook E., Pace P.E., Combes R. Ch., **Egly J.M.** and Ali S. Recruitment of the basal transcription factor TFIIH by oestrogen receptor a activation function AF-2 results in the phosphorylation of Serine 118 within activation Function AF-1 by cdk7. *Molecular Cell* (2000), 6, 127-137.
21. Schultz P., Fribourg S., Poterszmann, Mallouh V., Moras D. and **Egly J.M.** Molecular structure of Human TFIIH. *Cell*, (2000), 102, 599-607.
22. Vermeulen, W., Bergmann E., Auriol J., Rademakers S., Frit Ph., Appeldoorn E., Hoeijmakers J.H.J. and **Egly J.M.** Sublimiting concentration of TFIIH transcription/DNA repair factor causes the trichothiodystrophy TTD-A disorder. *Nature gen.* (2000), 26, 307-313. (N. & V. from J. Pettrini).
23. **Egly J.M.** TFIIH: from transcription to clinic. The 14th Datta Lecture. *FEBS Lett.* (2001), 24884,124-128.
24. Keriél A., Stary A., Sarasin A., Rochette-Egly C. and **Egly J.M.** XPD mutations prevent TFIIH dependent transactivation by nuclear receptor and phosphorylation of RAR α . *Cell* (2002), 109,125-135.
Preview : Mol Cell, 2002, and SAGE KE April 10, 2002 by J. Davenport.
25. Iben S., Tschochner H., Hoogsstraten D., Hozak P., **Egly J.M.** and Grummt I. TFIIH plays a role in RNA polymerase I transcription. *Cell* (2002), 109, 297-306.
26. Bradsher J., Auriol J., Proietti de Santis L., Iben S., Vonesch J.L., Grummt I. and **Egly J.M.** CSB is a component of RNA pol I transcription. *Molecular Cell* (2002), 10, 819-829.
27. Frit Ph., Kwon K., Coin F., Auriol J., Dubaele S., Salles B. and **Egly J.M.** Transcriptional activators stimulate DNA repair. *Molecular Cell* (2002), 10, 1391-1401.

28. Dubaele S., Proietti De Santis L., R. J. Bienstock, Keriel A., Stefanini M., B. Van Houten and **J.M. Egly**. Basal transcription defect discriminates between Xeroderma Pigmentosum and Trichothiodystrophy in XPD patients. *Molecular Cell* (2003), 11, 1635-1646.
29. Riedl Th., Hanaoka F. and **Egly J.M.** The comings and goings of nucleotide excision repair factors on damaged DNA, *EMBO* (2003), 22, 5293-5303.
30. Le May N., Dubaele S., Proietti de Santis L., Billecocq A., Bouloy M. and **Egly J.M.** TFIIH transcription factor, a target for the Rift Valley Hemorrhagic Fever Virus. *Cell*, (2004), 116, 541-550.
Preview : Mol Cell, 2004, A. Dasgupta.
31. Compe E, Drané P., Laurent C., Dietrich K., Braun C., Hoeijmakers J.H.J. and **Egly J.M.** Dysregulation of the Peroxisome Proliferator-Activated Receptors target genes by XPD mutations. *Mol. Cell. Biol.* (2005), 6065-6076
32. Drané P., Compe E., Catez Ph., Chymkowitch P. and **Egly J.M.** Selective regulation of vitamin D receptor-responsive genes by TFIIH. *Molecular Cell* (2004), 16, 187-197.
33. Coin F., Auriol J., Tapias A., Clivio P., Vermeulen W. and **Egly J.M.** Phosphorylation of XPB as a switch to regulate TFIIH dependent DNA repair but not transcription. *EMBO* (2004), 23, 4835-46.
34. Coin F., Proietti De Santis L., Nardo T., Zlobinskaya O., Stefanini M. and **Egly J.M.** Within TFIIH, p8/TTD-A directs repair whereas cdk-activating kinase/CAK directs transcription. *Molecular Cell* (2006), 21, 215-226.
35. Lainé J.Ph., **Egly JM.** Initiation of DNA repair mediated by a stalled RNA polymerase II. *EMBO* (2006), 25, 387-97.
36. Proietti-De-Santis L. Drané P. and **Egly J. M.** Cockayne syndrome B protein regulates the transcriptional program of a specific subset of genes. *EMBO* (2006), 25, 1915-1923.
37. Charlet-B. N., Feuerhahn S., Kong S. E., Ziserman H., Conaway J. W., Conaway R. and **Egly J. M.** RNA polymerase II bypass of oxidative DNA damage is regulated by transcription elongation factors. *EMBO* (2006), 25, 5481-91.
38. Ito S., Kuraoka I., Chymkowitch P., Compe E., Takedachi A., Ishigami C., Coin F., **Egly J.M.* and Tanaka K.** XPG is required for the integrity of TFIIH and transactivation besides nucleotide excision repair: Implications for Cockayne syndrome in XP-G/CS patients. *Molecular Cell* (2007), 26, 231-244. **Co-corresponding authors**
39. Coin F., Oksenysh V. and **Egly J.M.** DNA repair defect in Xeroderma pigmentosum group B is generated by a deficient stimulation of XPB ATPase activity by the p52 subunit of TFIIH. *Molecular Cell* (2007), 26, 245-256.
40. Compe E., Malerba M., Soler L., Marescaux J., Borrelli E. and **Egly J.M.** Neurological defects in Trichothiodystrophy reveal a coactivator function of TFIIH. *Nature Neuro* (2007), 10, 1423-32.
41. Mocquet V., Kropachev K., Kolbanovskiy M., Kolbanovskiy A., Tapias A., Cai Y., Broyde S., Geacintov N.E. and **Egly J.M.** The human DNA repair factor XPC distinguishes stereoisomeric benzo(a)pyrenyl-DNA lesions. *EMBO* (2007), 26, 2923-32
42. Mocquet V., Lainé J.Ph., Riedl T., Yajin Z., Lee M.Y., and **Egly J.M.** A new role for XPG in initiating a replication like process during the NER. *EMBO* (2008), 27,155-67.
43. **Coin F.**, Okshenysh V., Mocquet V., Groh S., Blattner C., and **Egly JM.** Nucleotide excision repair driven by the dissociation of CAK from TFIIH ; *Molecular Cell*, (2008), 31, 9-20. **Co-corresponding authors**
44. Kainov D. E., Vitorino M., Cavarelli J., Poterszman A. and **Egly JM.** Structural basis for group A Trichothiodystrophy. *Nat. Struc. Mol. Biol.* (2008), 15, 980-984.
45. Oksenysh V., Bernardes de Jesus B, Zhovmer A., **Egly J.M.* and Coin F.** Molecular insights into the recruitment of TFIIH to sites of DNA damage. *EMBO* (2009), 28, 2971-80. **Co corresponding authors**
46. Ueda T., Compe E., Catez Ph., Kraemer K.H. and **Egly JM.** Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients. *J. Exp. Med.* (2009), 206, 3031-3046. (*Preview: JEM*)
47. Le May N., Mota-Fernandes D., Vélez-Cruz R., Iltis I., Biard D. and **Egly J.M.** NER factors are recruited to the promoters of activated genes and help chromatin modifications for efficient transcription in the absence of genotoxic attack. *Molecular Cell* (2010), 38, 54-66.



(Cover of the issue)

48. Chymkowitch P., Le May N., Charneau P., Compe E., and **Egly J.M.** The Phosphorylation of the Androgen Receptor by TFIIH directs the ubiquitin/proteasome process. **EMBO** (2011), 30, 468-79.

49. Feuerhahn S., Giraudon C., Martínez-Díez M., Bueren-Calabuig J. A., Galmarini C. M., Gago F. and **Egly J.M.** XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic tetrahydroisoquinoline alkaloids. **Chemistry & Biology** (2011), 18, 988- 99.

(Cover of the issue)

50. Hashimoto S., Boissel S., Zarhate M., RIO M., Munnich A., **Egly J.M.**, **Colleaux L.** MED23 Mediator subunit mutation links intellectual disability to dysregulation of immediate early gene expression. **Science** (2011), 333, 1161-63. **Co corresponding authors.**




Last Five Years publications

51. Compe E. and **Egly J.M.** TFIIH When Transcription met DNA repair. **Nat. Rev. Mol. Cell Biol.** (2012), 13 343-354.

52. Le May N., Fradin D., Iltis I., Bougnères P. and **Egly J.M.** XPG and XPF endonucleases trigger chromatin looping and DNA demethylation for accurate expression of activated gene. *Molecular Cell* (2012), 47, 622-632. **Research Highlights: Nat. Rev. Genetics** (2012), 13, 519.

53. Le May N., Iltis I., Amé J.C., Zhovmer A., Biard D., **Egly J.M.**, Schreiber V. and Coin F.: Poly (ADP-Ribose) glycohydrolase regulates RAR mediated gene expression. **Molecular Cell** (2012), 48, 785-798 (Cover of the issue).



54. Vélez-Cruz R., Zadorin A., Coin F. and **Egly J.M.** Sirt1 regulates RNA synthesis after UV irradiation in TFIIH-mutated cells: new insight into the XP-D/CS cellular phenotype. **PNAS** (2013), 110, 814-815; E212-20.

55. Abdulrahman W., Iltis I., Radu L., Braun C., Maglott-Roth A., Giraudon Ch., **Egly J.M.** and Poterszman A. The ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and Transcription Activities. *PNAS*. (2013), 110, E633-42 **Co corresponding authors**

56. Oksenysh V, Zhovmer A, Ziani S, Mari PO, Eberova J, Nardo T, Stefanini M, Giglia-Mari G, **Egly J.M.**, Coin F. Histone Methyltransferase DOT1L Drives Recovery of Gene Expression after a Genotoxic Attack. **PLoS Genet** (2013), 9, 7, e1003611.

57. Kristensen U., Epanchintsev A., Rauschendorf M.A., Laugel V., Stevnsner T., Bohr V.A., Coin F. and **Egly J.M.** Regulatory interplay of Cockayne Syndrome B ATPase and stress-response gene ATF3 following genotoxic stress. **PNAS** (2013), 110, E2261-2270.

58. Alekseev A., Ayadi M., Brino L., **Egly J.M.**, Larsen A.K. and Coin F. Identification of Spirolactone as a DNA repair inhibitor inducing the degradation of TFIIH. *Chemistry & Biology* (2014), 21, 398-407.

59. Bour G., Martel F., Goffin F., Bayle B., Gangloff J., Aprahamian M., Marescaux J. and **Egly J.M.** Design and Development of a robotized system coupled to μ CT imaging for intratumoral drug evaluation in a HCC mouse model; *Plos One* (2014), in press.

60. Kuper J., Braun C., Elias A., Michels G., Schmitt D.R., Poterszman A., **Egly* J.M.** and Kisker* C. The two faces of XPD during transcription initiation and Nucleotide Excision DNA repair **Plos Biol.** (2014), in press,***Co corresponding author.**

61. Traboulsi H., Davoli D., Catez Ph., **Egly* J.M.** and Compe* Dynamic partnership between TFIIH, PGC-1 and SIRT1 is impaired in premature-ageing disease. **Plos Biol.** (2014), in press, ***Co corresponding author**

62. Ziani S, Nagy Z, Alekseev S, Soutoglou E, **Egly J.M.**, **Coin F.** Sequential and ordered assembly of a large DNA repair complex on undamaged chromatin. **J Cell Biol.** (2014), 206, 589-98

63. Singh A., Compe E., **Le May N.** and **Egly J.M.** Mutations in genes encoding TFIIH subunits causing xeroderma pigmentosum and trichothiodystrophy disorders specifically disturb several steps during transcription. **AJHG** (2015) 96,194-207

64. Kim J., Lim H., Saint-André C., Kim J., Sung S., Hwang CS., **Egly J.M.***, and Cho Y*. The crystal structure of the Rad3/XPD regulatory domain of Ssl1/p44: Insights into regulation of the helicase activity of the XPD subunit of TFIIH, *J. Bio. Chem.* (2015), 290(13):8321-30. *Co corresponding author

65. Coin F, **Egly J.M.** Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor. **Mol Cell.** (2015), 59, 513-4.

66. Santamaría Nuñez G., Genes Robles C.M., Giraudon, G. Martínez-Leal J.F., Compe E., Coin F., Pablo Aviles, Galmarini C. M. and **Egly J.M.*** Lurbinectedin specifically triggers the degradation of phosphorylated RNA Polymerase II and the formation of DNA breaks in cancer cells, **Mol Cancer Ther.** (2016), 15(10):2399-2412.

67. Compe E. and **Egly J.M.*** Nucleotide Excision Repair and Transcriptional Regulation: TFIIH and Beyond; Annual Review of Biochemistry (2016), 85, 265-90.

68. Anastasina M, Le May N, Bugai A, Fu Y, Söderholm S, Gaelings L, Ohman T, Tynell J, Kytönen S, Barboric M, Nyman TA, Matikainen S, Julkunen I, Butcher SJ, **Egly JM***, Kainov DE. *Biochim Biophys Acta.* (2016), 1859(11):1440-48.

2017

Arseni D., Lanzafame M., Compe E., Fortugno P., Afonso-Barroso A., Peverali F.a., Lehmann A.R., Zambruno G., **Egly J.M.**, Stefanini M., Orioli D. TFIIH-dependent MMP-1 overexpression in trichothiodystrophy leads to extracellular matrix alterations in patient skin. **PNAS** (2015), 112, 1499-504

Singh A., Compe E., **Le May N.** and **Egly J.M.*** Mutations in genes encoding TFIIH subunits causing xeroderma pigmentosum and trichothiodystrophy disorders specifically disturb several steps during transcription. **AJHG** (2015) 96, 194-207.

Kim J., Lim H., Saint-André C., Kim J., Sung S., Hwang CS., **Egly J.M.***, and Cho Y*. The crystal structure of the Rad3/XPD regulatory domain of Ssl1/p44: Insights into regulation of the helicase activity of the XPD subunit of TFIIH, *J. Bio. Chem.* (2015), 290(13):8321-30. *Co corresponding author

Coin F, **Egly J.M.*** Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor. **Mol Cell.** (2015), 59(4):513-4.

2016

Compe E. and **Egly J.M.*** Nucleotide Excision Repair and Transcriptional Regulation: TFIIH and Beyond; **Annual Review of Biochemistry** (2016), 85, 265-90.

Anastasina M, Le May N, Bugai A, Fu Y, Söderholm S, Gaelings L, Ohman T, Tynell J, Kytönen S, Barboric M, Nyman TA, Matikainen S, Julkunen I, Butcher SJ, **Egly J.M.***, Kainov DE. *Biochim Biophys Acta.* (2016), 1859(11):1440-1448.

Santamaría Nuñez G., Genes Robles C.M., Giraudon, C., Martínez-Leal J.F., Compe E., Coin F., Pablo Aviles, Galmarini C. M. and **Egly J.M.*** Lurbinectedin specifically triggers the degradation of phosphorylated RNA Polymerase II and the formation of DNA breaks in cancer cells. **Mol Cancer Ther.** (2016), 15(10):2399-2412.

2017

Alekseev S., Nagy Z. Sandoz J., Weiss A., **Egly J.M.**, Le May N. and Coin F. Transcription without XPB establishes a unified helicase-independent mechanism of promoter opening in eukaryotic gene expression **Molecular Cell** (2017), 65, 504-514.

Donnio L-M., Bidon B., Haschimoto S., May M., Epantchintsev A., Ryan C., Allen W., Hackett A., Gecz J., Skinner C., Stevenson R. E., de Brouwer A. P.M., Coutton C., Francannet C Jouk. P-S, Schwartz C. E. and **Egly J.M.*** MED12-related XLID disorders 1 are dose-dependent of immediate early genes 2 (IEGs) expression; **HMG** (2017), 11, 2062-2075

Radu L., Schoenwetter E., Braun C., Marcoux J., Koelmel W., Schmitt D. R., Kuper J., Cianferani S., **Egly J.M.**, Poterszman A. and Kisker C. The intricate network between the p34 and p44 subunits is central to the activity of the transcription/DNA repair factor TFIIH: *Nuc. Acid Res.* (2017), 45, 10872-10883.

Epantchintsev A., Costanzo F., Rauschendorf M-A., Caputo M., Ye T., Donnio L.M., Proietti-de-Santis L., Coin F., Laugel V. and **Egly J.M.*** Cockayne syndrome A and B proteins regulate the timing of transcription arrest upon genotoxic stress through a ubiquitin/proteasome degradation process. **Molecular Cell** (2017), 68, 1054-1066.

2018

Bidon B, Iltis I, Semer M, Nagy Z, Larnicol A, Cribier A, Benkirane M, Coin F, **Egly J.M.***, Le May N. XPC is an RNA polymerase II cofactor recruiting ATAC to promoters by interacting with E2F1. **Nat Com.** (2018); 9(1):2610.

2019

Compe E., Genes C.M., Braun C., Coin F. and **Egly J.M.***. TFIIIE orchestrates the recruitment of the TFIIH kinase module at promoter before their release during transcription. **Nat Com.** 2019, *in press*.

Sandoz J., Nagy Z., Catez Ph., Caliskan G., Gény S., Renaud JB, Concordet JP, Poterszman A., Tora L., **Egly J.M.**, Le May N. and Coin F. Functional interplay between TFIIH and the histone acetyl transferase KAT2A regulates higher-order chromatin structure and class II gene expression. **Nat Com.** 2019, *in press*.

Nizon M., Laugel V., Flanigan K., M., **Egly J.M.** and Isidor B. Variants in *MED12L*, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcription defect. **Gen. in Med.**, 2019, *in press*.

Paccosi E., Costanzo F, Costantino M, Monteonofrio L, Soddu S, Prantera G, **Egly J.M*** and Proietti De Santis*:CSA and CSB, as part of a Ubiquitin-Proteasome degradation machinery regulate the abscission during cytokinesis (submitted).